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Abstract
Introduction: Borderline personality disorder is a chronic mental disorder associated with severe




Case presentation: Authors reported the case of a 37-year-old obese woman with borderline
personality disorder, obsessive-compulsive symptoms and bulimia nervosa treated with aripiprazole
and topiramate. Co-administration of aripiprazole and topiramate produced a significant improve-
ment of all psychopathological dimensions, obsessive-compulsive symptoms, and eating disorder.
Conclusion: Co-administration of aripiprazole and topiramate could be a safe and effective long-
term treatment for improving not only the symptoms of borderline personality disorder but also the
associated health-related quality of life and interpersonal problems.
Introduction
Borderline personality disorder (BPD) is condition diffi-
cult to treat [1] which is characterized by three main
psychopathologic dimensions: impulsiveness, an unstable
sense of self with difficulty in interpersonal relationships
and affective instability [2,3].
Although psychotherapy has been the main therapeutic
approach for the disorder, current guidelines state that
pharmacotherapy is indicated to manage state symptoms
and trait vulnerabilities. Long-term treatment is necessary
and although there is no drug with an approved indication
for BPD, many drugs have showed efficacy on borderline
symptomatology, improving the course of the disorder
and making possible to conduct psychotherapeutical work
with more beneficial results. Among available drugs, apart
from SSRIs, the novel antipsychotic olanzapine emerges as
one of the most studied pharmacological agents for short-
term management of BPD; its administration, although
effective, is often associated with weight increase and,
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regard to potential complications in comorbid eating
disorders in BPD populations [4].
Authors reported a case of BPD with obesity, obsessive-
compulsive symptoms and bulimia nervosa treated with
aripiprazole and topiramate; besides the efficacy on BPD
symptomatology [5-9], the therapeutic choice was
oriented considering that both substances had favourable
tolerability profile and a low propensity to cause weight
gain, dyslipidemia, glucose dysregulation and metabolic
syndrome [10-11].
Case presentation
The patient is a 37-year-old Caucasian-Italian woman,
unmarried, of medium socio-cultural level; the sympto-
matological onset (tendency to isolation, deflected mood,
somatizations) dated at the age of 16 years old. Not-
withstanding those symptoms, she maintained an accep-
table level of functioning until the age of 22 years old,
when, in relation with her father’s illness that would have
led him to death within ten years, she displayed a
symptomatology characterized by social withdrawal, and
behavioural and eating disorders. From the age of 22 years
to the age of 35 years, she was treated for Major Depressive
Disorder with atypical antipsychotics, antidepressants,
benzodiazepines, and psychotherapeutic interventions.
Treatments were only partially effective. When, for the
persistent symptoms and for the onset of serious family
conflicts, she was referred at our Unit, in September 2006,
weighting 123 Kg (BMI = 45) and completely toothless,
she suffered from arterial hypertension and type 2 diabetes
mellitus (fasting phase glycaemia = 15.5 mmol/l). For the
psychiatric and clinical conditions, she was assuming the
following pharmacological therapy: risperidone 2 mg/day,
sertraline 50 mg/day, delorazepam 1 mg × 2/day, enalapril
20 mg/day, metformine 1000 mg × 3/day.
The clinical interview evidenced depressive mood, lack of
self-esteem with explicit mistrust towards the possibility
to be helped, a pervasive feeling of emptiness, fear of
contamination with repeated hand washing, and intense
anxiety. Regarding socio-relational functioning, her rela-
tionships were superficial and characterized by impulsivity
and intense anger; towards her relatives, she constantly
tended to ascribe them the responsibility and the guilt for
her situation. Unable to recognize a link between her own
emotions and life events, she immediately translated
affective states in bodily correlates with a tendency to
privilege a psychosomatic focus (the contact of her skin
with fabrics different from silk caused her reddening and
itch). Moreover, she exhibited a presumed intolerance
towards smells and almost all the materials (wood, paper,
steel). She also displayed an eating disorder marked by
compulsive overeating without purging behaviours
(Bulimic type). The patient underwent neurological
examination with EEG, and allergologic visit with patch
test which excluded any organic nature of the symptoms.
The patient underwent a psychodiagnostic assessment
which included: Borderline Personality Disorder Scale
(BPD-Scale), Hamilton Rating Scale for Depression
(HAM-D), Hamilton Anxiety Scale (HAM-A), Yale-Brown
Obsessive Compulsive Scale (Y-BOCS), Bulimia Test-
Revised (BULIT-R). The results of the assessment were as
follow: BPD-scale = 40, HAM-D = 35, HAM-A = 41,
Y-BOCS = 35, BULIT-R = 94 (Figure 1).
She was though diagnosed, according to DSM-IV criteria,
as Borderline Personality Disorder with comorbid Obses-
sive-Compulsive Disorder and Bulimic Disorder; due to
persistent symptoms and non-response to previous treat-
ments, pharmacological treatment was accordingly mod-
ified by the progressive reduction until suspension of
risperidone and sertraline and the introduction of
aripiprazole 5 mg/day and topiramate up to 200 mg/
day; the topiramate final dosage was reached within 4
weeks. Antihypertensive and hypoglycemic therapies were
left unchanged; moreover, the patient engaged in suppor-
tive psychotherapy.
At one yearfollow-up, the combinedtreatment produced a
significant improvement in mood and in socio-relational
functioning; the patient also decided for the realization
of a dental prosthesis. Gradually, obsessive thoughts and
Figure 1. Total scores of rating scales at baseline and after
1 year and 2 years of aripiprazole plus topiramate treatment.
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was able to wear whichever fabric); eating behaviour
became more regular and the frequency of binge eating
episodes decreased. Moreover, she began to collaborate
with the cook in the preparation of meals and to give
private lessons to the patients referred to our unit.
A second psychodiagnostic assessment at the end of the
first year of treatment evidenced the following results:
HAM-D=15,HAM-A=9,Y-BOCS=6,BULIT-R=81(Figure1).
During the second year of treatment, a psychosomatic
symptomatology related to the genital area emerged
(reddening and itch). Considering the obtained results
and the global functioning of the subject, it has been
decided to leave unchanged pharmacological therapy and
to continue psychotherapy with the aim to support the
development of an independent self able to manage
conflicts, the strengthening of ego functions, and the
elaboration of the psychological abuse.
At two years follow-up, the improvement in psychopathol-
ogy was furtherly maintained and consolidated; the
patient went back home, her socio-relational functioning
was marked by a greater degree of autonomy and a better
control on emotional states and impulsivity. The final
psychodiagnostic assessment at the end of the second year
of treatment showed a further reduction of total scores:
HAM-D = 6, HAM-A = 6, Y-BOCS = 3, BULIT-R = 56
(Figure 1).
Moreover, during the treatment a progressive loss of
weight occurred (the patient actually weights 90 kg - BMI =
33) as well as the normalization of the glycaemic values
(fasting phase glycaemia = 4.3 mmol/l) with the
consequent discontinuation of the hypoglycaemic
treatment; although antihypertensive therapy remained
unchanged, blood pressure values were enough stable.
It can be observed that the 24-months treatment was
effective in reducing depressed mood, anger outbreaks,
anxiety, psychosomatic and obsessive symptoms, and,
globally, socio-relational functioning.
Discussion
Borderline personality, a pervasive disorder which has
importantclinicalandsocialrepercussions,hasbeenmainly
treated by psychotherapy. In recent years, the syndromic
analysis of this disorder has allowed us to identify different
symptoms susceptible of improvement with psychophar-
macology treatment. Antidepressants, mood stabilizers,
antipsychotics and benzodiazepines have shown efficacy
inthetreatmentofsymptomaticdimensionsofthedisorder.
From a neurobiological point of view, a rationale exists for
drugs acting on the dysfunction of those neurotransmitters
that mediate behavioural responses and temperamental
traits of vulnerability, mood, anxiety, and psychotic
symptoms, and, finally, comorbid psychopathology. In
particular, low levels of serotonine, cortical dopamine
deficit and GABAergic deficit are considered as possible
causes respectively for impulsivity, cognitive distortion, and
emotional instability [4].
Aripiprazole is a novel antipsychotic, successfully
employed for the treatment of schizophrenia and bipolar
disorder, acting as partial agonist at dopamine D2 and
serotonin 5-HT1A receptors and as antagonist at 5-HT2A
[12]. Because of its ability to stabilize dopaminergic and
serotonergic systems, aripiprazole may represent a new
treatment approach for many other psychiatric disorders
such as resistant depression, anxiety, obsessive compulsive
disorder and BPD [13]. Aripiprazole exhibited a favorable
safety and tolerability profile, with a low propensity
to cause extrapyramidal symptoms, weight gain,
cardiovascular abnormalities, hyperprolactinemia,
hypercholesterolemia, or glucose dysregulation; however
in phase 3 of the CATIE schizophrenia trial, unlike
previous findings, it was associated with greater increa-
ses in blood glucose than all of the other treatment
regimens [14].
Topiramate is an anticonvulsant and its multifactorial
action mechanisms include blockade of voltage-
dependent sodium channels, potentiation of GABAergic
transmission and inhibition of excitatory pathways
through an action at AMPA receptor sites [15]. Topiramate
has shown a documented effect on the reductions of
impulsive behaviours, such as alcohol and cocaine use,
binge eating and purge behaviours in bulimia nervosa,
and aggression in borderline personality disorder [16].
Based on this evidence, the association aripiprazole plus
topiramate may represent a promising treatment for BPD
and concurrent psychiatric disorders.
The clinical case reported has evidenced that previous
treatments with atypical antipsychotics, SSRI and benzo-
diazepine did not resulted effective in improving the
exhibited symptomatology; concurrently, the onset of
significant metabolic problems (pronounced weight
increase, hyperglycaemia) was observed.
Contrarily, the co-administration of aripiprazole plus
topiramate induced a significant and longlasting improve-
ment both of overall symptomathology, that is, the BPD
core symptoms and comorbid conditions (obsessive
symptoms, somatizations and eating disorder); a signifi-
cant improvement of dysmetabolic aspects (weight loss,
normalization of glycemic levels) also occurred. Result
were coherent with previous studies demonstrating the
efficacy and tolerability of both aripiprazole and
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that is showed by the improvement of core symptoms of
the disorder and, moreover, of quality of life and of socio-
relational dysfunctions in borderline patients.
Conclusions
Aripiprazole and topiramate co-administration could be
a safe and effective long-term treatment for improving
symptoms of Borderline Personality Disorder. To the best
of our knowledge, scientific literature is actually lacking of
controlled trials aimed to test the efficacy and the
tolerability of the combination topiramate plus aripipra-
zole for the treatment of major psychiatric disorders, and
of personality disorders, including BPD. Starting from the
clinical experience presented in this case report, it would
be therefore interesting to design controlled studies with
the aim of evaluating the combination of aripiprazole plus
topiramate in selected populations of psychiatric patients.
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